Rajat Deo is a Cardiology physician. OpenAlex indexes 332 publications with 31,257 citations (h-index 56). By OpenAlex citation count, this profile ranks in the top 5% of Clinical Cardiac Electrophysiology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St Fl 2
Philadelphia, PA 191044229
Telephone
215-615-4949Provider last certified this registry record 6 Feb 2026.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Boston Scientific CorporationProgram year20259 payments
- Abbott LaboratoriesProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Integrating Large-Scale Proteomics and Genomics for the Biological Characterization of Ischemic Stroke in REGARDS
University of Pennsylvania
FY2026$703,249R01NS141408 - Dynamic Longitudinal Functional Models with Applications to the CRIC Study
University of Pennsylvania
FY2025$694,185R01HL161303 - Dynamic Longitudinal Functional Models with Applications to the CRIC Study
University of Pennsylvania
FY2024$680,301R01HL161303
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
The Lancet Diabetes & Endocrinology
2023 - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
The Lancet Diabetes & Endocrinology
2023 - Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Nephrology Dialysis Transplantation
2022 - The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury
JACC Basic to Translational Science
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”